Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

Symphogen A/S57 enrolled

Overview

This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.

In the first part of the study (Part 1, dose-escalation), Sym015 was evaluated for safety and tolerability. Additionally, the recommended Phase 2 dose (RP2D) was to be determined. Sym015 was given at different dose levels on an every second week (Q2W) dosing schedule. Each patient was given one single weight based dose level. In the second part of the study (Part 2, dose-expansion), dosing was to be at the RP2D on a Q2W dosing schedule. Three cohorts were included: * Basket Cohort: Patients with KRAS wild-type (WT) advanced solid tumor malignancies with MET-amplification and without therapeutic options. Patients must have no prior therapy with MET-targeting agents, except a subset of patients having received prior therapy with a MET-targeting tyrosine kinase inhibitor (TKI). As of December 2018, accrual to this cohort was suspended. * Non-Small Cell Lung Carcinoma (NSCLC) MET-Amplified Cohort: Patients with advanced NSCLC with MET-amplification, and without available therapeutic options. Patients may have received prior therapy with MET-targeting and/or epidermal growth factor receptor (EGFR)-targeting agents. * NSCLC with MET exon 14 skipping alteration (METex14del) Cohort: Patients with advanced NSCLC METex14del, and without therapeutic options. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Oncology MET Gene Amplification NSCLC MET Gene Mutation Non Small Cell Lung Cancer

Interventions

Sym015DRUG

Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. * Life expectancy \>3 months assessed during Screening. * Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic, and that is refractory to standard therapy or for which no standard therapy is available or accessible. * If female and of childbearing potential: a negative pregnancy test. * Male or female: either not of childbearing potential or agreeing to use a medically effective method of contraception as per institutional standards during the trial and for 4 months after the last dose of trial drug. * Part 1 ONLY: Tumor documented to be KRAS WT by local assessment. * Part 2 ONLY: * Measurable disease according to RECIST v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle 1/Day 1 (C1/D1). * Basket Cohort ONLY: * Tumor documented to be KRAS WT by local assessment according to institutional standards. If KRAS WT is not previously documented and if archival tissue is not available for pretrial assessment, patient must be willing to undergo a tumor biopsy to confirm eligibility. * Confirmed MET-amplification by local assessment. * No prior therapy with MET-targeting agents (except a subset of patients having received prior therapy with a MET-targeting TKI). * Willingness to undergo a pre- and post-dosing biopsy (maximum of 2 biopsies) from primary or metastatic tumor site(s) considered safely accessible for biopsy * NSCLC MET-Amplified Cohort ONLY: * Documented NSCLC meeting disease criteria as defined per protocol. * Documented MET-amplification. * May have received prior therapy with MET-targeting and/or EGFR-targeting agents (antibodies or TKIs). * Willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the End of Cycle 2 (EOC2) (optional), from a primary or metastatic tumor site considered safely accessible for biopsy. * NSCLC METex14del Cohort ONLY: * Documented NSCLC meeting disease criteria as defined per protocol. * Documented METex14del (tumors need not be MET-amplified). * May have received prior therapy with MET-targeting and/or EGFR-targeting agents (antibodies or TKIs). * Willingness to undergo a pre-dosing biopsy (mandatory unless a recent tumor biopsy is available), and potentially a biopsy at the EOC2 (optional), from a primary or metastatic tumor site considered safely accessible for biopsy. Exclusion Criteria: * Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to C1/D1, except nitrosoureas and mitomycin C within 6 weeks prior to C1/D1. * Immunosuppressive or systemic hormonal therapy within 2 weeks prior to C1/D1, with exceptions. * Use of hematopoietic growth factors within 2 weeks prior to C1/D1. * Active second malignancy or history of another malignancy within the last 3 years, with exceptions. * Central nervous system (CNS) malignancy including primary malignancies of the CNS and known, untreated CNS or leptomeningeal metastases, or spinal cord compression; patients with any of these not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required. * Inadequate recovery from an acute toxicity associated with any prior antineoplastic therapy. * Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any prior surgical procedure. * Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 1 month prior to C1/D1, unless adequately treated and stable. * Active uncontrolled bleeding or a known bleeding diathesis. * Significant cardiovascular disease or condition. * Abnormal hematologic, renal or hepatic function. * Part 2 ONLY: * Radiotherapy against target lesions within 4 weeks prior to C1/D1, unless there is documented progression of the lesion following the radiotherapy. * Basket Cohort ONLY: * Prior therapy with MET-inhibiting agents (exceptions will be a subset of patients that will be entered to the Basket Cohort after having received prior therapy with a MET-targeting TKI). * Prior therapy with antibody to hepatocyte growth factor (HGF). * Basket Cohort and NSCLC MET-Amplified Cohort ONLY: * Tumor status demonstrating MET-polysomy in the absence of MET-amplification, as specified per protocol. Patients in the NSCLC METex14del Cohort with polysomy are eligible.

Locations (27)

Outcomes

Primary Outcomes

Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration

The primary objective of Part 1 was to assess the safety and tolerability of Sym015 on a Q2W schedule. This was assessed by evaluating the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration. Q2W = every second week.

Time frame: Cycle 1, the initial 28-day period of Q2W dosing

Part 2: Documented, Confirmed Objective Response (OR)

The primary objective of Part 2 was to evaluate the antitumor activity of Sym015 when administered at the Q2W RP2D to patients in the different cohorts. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Q2W = every second week. RP2D = recommended phase 2 dose.

Time frame: 24 months

Secondary Outcomes

Part 1: Determine a Q2W RP2D of Sym015.

Determination based on an evaluation of the patient data for DLTs from Part 1. Q2W = every second week. RP2D = recommended phase 2 dose.

Time frame: 12 Months

Immunogenicity of Sym015: Part 1.

Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.

Time frame: Cycle 1: Day (D) 1, Cycle 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)

Immunogenicity of Sym015: Part 2.

Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

University of Colorado Cancer Center

Aurora, Colorado, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Indiana University Health Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute/D -1251

Boston, Massachusetts, United States

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

The University of Texas M.D. Anderson Cancer Center

Houston, Texas, United States

South Texas Accelerated Research Therapeutics, LLC

San Antonio, Texas, United States

...and 17 more locations

Time frame: Cycle 1: Day (D) 1, Cycle 2, 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)

Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose

Estimated using non-compartmental methods and actual time points following the first dose of Sym015.